(Q44216350)

30 November 2017

Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases (English)

1 reference

30 November 2017

1 reference

1 reference

Garcia VD

1

1 reference

30 November 2017

Bonamigo-Filho JS

2

1 reference

30 November 2017

Neumann J

3

1 reference

30 November 2017

Fogliatto L

4

1 reference

30 November 2017

Gaiger AM

5

1 reference

30 November 2017

Garcia CD

6

1 reference

30 November 2017

Barros V

7

1 reference

30 November 2017

Keitel E

8

1 reference

30 November 2017

Bittar AE

9

1 reference

30 November 2017

Santos AF

10

1 reference

30 November 2017

Roithmann S

11

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Transplantation Proceedings

30 November 2017

1 reference

30 November 2017

34

1 reference

30 November 2017

2993-2995

1 reference

30 November 2017

7

1 reference

Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Lymphoproliferative disorders after organ transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid o

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Treatment of lympho-proliferative disease with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Rapamycin (sirolimus, rapamune).

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903511-X

7 January 2021

10.1016/S0041-1345(02)03511-X

Identifiers

DOI

1 reference

30 November 2017

1 reference